Background: To date, clinical experience with prothrombin complex concentrate (PCC) in
the neonatal population has been limited. Aim: The objective of this study was to describe …

Coagulation disturbances frequently occur in critically ill children. Four-factor prothrombin
complex concentrate (4F-PCC) may have a potential role in managing these patients while …

To systematically evaluate the effectiveness of prothrombin complex concentrate (PCC) in
neonates and infants, we performed a systematic review and meta-analysis based on …

Background Four‐factor prothrombin complex concentrates (PCC s) are human plasma‐
derived products containing coagulation factors II, VII, IX and X as well as proteins C and S …

Neonate (≤ 31 days of age) 3 (18%) Infant (< 1 year of age) 3 (18%) Child (1-12 years of
age) 6 (35%) Adolescent (13-18 years of age) 3 (18%) Adult (> 18 years of age) 2 (12%) …

Cardiovascular surgery in pediatric patients is associated with a greater risk of bleeding and
blood transfusions in approximately 79% of procedures. 1, 2 4-factor prothrombin complex …

Pediatric cardiac surgery patients are predisposed to blood loss. Blood product
administration can lead to complications. Prothrombin complex concentrates (PCCs) offer …

Various factors may lead to coagulation disturbances following cardiopulmonary bypass and
surgery for congenital heart disease. In addition to the risks associated with the …

The 3-factor prothrombin complex concentrate (3FPCC) may be used off-label to treat
refractory bleeding during cardiac surgery in children. This retrospective study examined the …

Prothrombin complex concentrates (PCCs) are used to manage bleeding in critically ill
children. We performed a repeat cross-sectional study using the Pediatric Health Information …